1

Convatec Group

#2481

Rank

$6.01B

Marketcap

GB United Kingdom

Country

Convatec Group
Leadership team

Mr. Karim Bitar (CEO & Director)

Mr. Jonathan P. Mason (Group CFO & Director)

Mr. Donal Balfe (Exec. VP and Chief of Quality & Operations)

Products/ Services
Clinical Trials, Health Care, Manufacturing, Medical
Number of Employees
1,000 - 20,000
Headquarters
Reading, Reading, United Kingdom
Established
1978
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
CTEC.L
Social Media
Overview
Location
Summary
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
History

The company was established as a division of E.R. Squibb & Sons, Inc. in 1978 and acquired by Nordic Capital and Avista Capital Partners in 2008. In 2008 merged with Unomedical , a manufacturer of single-use medical devices,

and 180 Medical, a catheter manufacturer, in 2012.In June 2015 the company won a Court of Appeal ruling that determined that in the context of a patent "between 1% and 25%" should be interpreted rounding to the nearest 1%, so that an attempt to circumvent a patent by using the value 0.9% failed. In October 2016 the company was valued at £4.4bn in the largest initial public offering on the London Stock Exchange in the year.On 15 October 2018, Convatec announced that Paul Moraviec would be retiring as CEO with immediate effect, and would be succeeded on an interim basis by non-executive director Rick Anderson, who was formerly the chairman of Johnson & Johnson.On 25 March 2019, Convatec announced Karim Bitar, formerly CEO of Genus Plc, had been appointed CEO and would join the business on 30 September 2019. Prior to Genus, Karim spent 15 years in various roles with increasing responsibility at Eli Lilly where from 2008 he was President of Europe, Australia and Canada, leading an organisation with annual sales of approximately US$5 billion per year.

On 19 August 2019, Convatec announced Dr John McAdam CBE would become Chairman, effective 30 September, the same day Karim Bitar became CEO.

Mission
Convatec's mission is to provide innovative, high-quality and cost-effective medical solutions that empower people with chronic conditions to live better lives.
Vision
Our vision is to become the premier partner to health care providers, empowering people with chronic conditions to live their best life.
Key Team

Dr. Divakar Ramakrishnan Ph.D. (Exec. VP & Chief Technology Officer)

Mr. Mark Reynolds (Director of Investor Relations)

Ms. Kate Postans (VP of Investor Relations & Corp. Communications)

Ms. Natalia Kozmina (Exec. VP & Chief HR Officer)

Mr. Christian Hoengaard (Sr. VP & GM - USA)

Ms. Kjersti Grimsrud Biotechnology, M.Sc. (Pres & COO of Infusion Care)

Mr. Supratim Bose (Pres & COO of Global Emerging Markets)

Recognition and Awards
Convatec has won numerous awards including being named a 2018 Top Employer in the UK and being recognized as one of the 100 Best Companies to Work For by Working Mother Magazine for four consecutive years.
References
Convatec Group
Leadership team

Mr. Karim Bitar (CEO & Director)

Mr. Jonathan P. Mason (Group CFO & Director)

Mr. Donal Balfe (Exec. VP and Chief of Quality & Operations)

Products/ Services
Clinical Trials, Health Care, Manufacturing, Medical
Number of Employees
1,000 - 20,000
Headquarters
Reading, Reading, United Kingdom
Established
1978
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
CTEC.L
Social Media